SG11201809976PA - Protection of plant extracts and compounds from degradation - Google Patents

Protection of plant extracts and compounds from degradation

Info

Publication number
SG11201809976PA
SG11201809976PA SG11201809976PA SG11201809976PA SG11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA
Authority
SG
Singapore
Prior art keywords
international
cannabinoids
pct
degradation
street
Prior art date
Application number
SG11201809976PA
Inventor
Luis Vitetta
Sean Hall
Original Assignee
Medlab Ip Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901758A external-priority patent/AU2016901758A0/en
Application filed by Medlab Ip Pty Ltd filed Critical Medlab Ip Pty Ltd
Publication of SG11201809976PA publication Critical patent/SG11201809976PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 1111111111111111111101110111111110111011111111110111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/193169 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: A61K 31/352 (2006.01) A61K 47/44 (2017.01) A61K 47/10 (2017.01) (21) International Application Number: PCT/AU2017/050430 (22) International Filing Date: 11 May 2017 (11.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016901758 11 May 2016 (11.05.2016) AU (71) Applicant: MEDLAB IP PTY LTD [AU/AU]; 66 Mc- Cauley Street, Alexandria, New South Wales 2015 (AU). (72) Inventors: VITETTA, Luis; 6 Mulgrave Crescent, Varsi- ty Lakes, Queensland 4227 (AU). HALL, Sean; 2301/168 Kent Street, Millers Point, New South Wales 2000 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; 255 Elizabeth Street, Sydney, New South Wales 2000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind ARIPO GH, of regional protection available): (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) Il C:r SO 1-1 (54) Title: PROTECTION OF PLANT EXTRACTS AND COMPOUNDS FROM DEGRADATION en 0\ (57) : Provided herein are methods for protecting cannabinoids, typically in medicinal compositions, from heat-, sunlight- or 1-1 ---- artificial- light-induced degradation, and oxidative degradation due to contact with ambient air/oxygen. Also provided are methods for IN extending the shelf life, stability, and long term viability and efficacy of cannabis- and cannabinoid-containing medicinal compositions. © Said cannabinoids are protected by providing the one or more cannabinoids in a composition comprising at least one non-ionic surfactant N and at least one polyol. O
SG11201809976PA 2016-05-11 2017-05-11 Protection of plant extracts and compounds from degradation SG11201809976PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901758A AU2016901758A0 (en) 2016-05-11 Protection of plant extracts and compounds from degradation
PCT/AU2017/050430 WO2017193169A1 (en) 2016-05-11 2017-05-11 Protection of plant extracts and compounds from degradation

Publications (1)

Publication Number Publication Date
SG11201809976PA true SG11201809976PA (en) 2018-12-28

Family

ID=60266066

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809976PA SG11201809976PA (en) 2016-05-11 2017-05-11 Protection of plant extracts and compounds from degradation

Country Status (6)

Country Link
US (2) US20190315704A1 (en)
EP (1) EP3454849A4 (en)
AU (1) AU2017261847B2 (en)
CA (1) CA3023767A1 (en)
SG (1) SG11201809976PA (en)
WO (1) WO2017193169A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US20210315818A1 (en) * 2018-08-20 2021-10-14 Hexo Operations Inc. Cannabinoid based emulsion systems for infused non-aqueous compositions
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20200188301A1 (en) 2018-12-14 2020-06-18 NuVessl, Inc. Method for Enhancing Passenger Molecule Loading
CN110038251B (en) * 2019-05-30 2021-07-30 汉义生物科技（北京）有限公司 A method for degrading cannabinoid
CA3149652A1 (en) * 2019-08-08 2021-02-11 Neptune Wellness Solutions Inc. Oral formulations of cannabis extracts and methods of making same
IT202100014909A1 (en) * 2021-06-08 2022-12-08 Velleja Res S R L OILY FORMULATIONS OF CANNABINOIDS
US20230036051A1 (en) * 2021-07-21 2023-02-02 Resurgent Biosciences, Inc. Cannabinoid storage stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
CN101516333A (en) * 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 Aqueous dronabinol formulations
JP2010535774A (en) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド Oral cannabinoid liquid formulations and methods of treatment
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CN103110582A (en) * 2013-03-04 2013-05-22 上海医药工业研究院 Cannabinol compound micro-emulsion and preparation method thereof

Also Published As

Publication number Publication date
WO2017193169A1 (en) 2017-11-16
CA3023767A1 (en) 2017-11-16
US20220274943A1 (en) 2022-09-01
US20190315704A1 (en) 2019-10-17
EP3454849A4 (en) 2019-11-27
EP3454849A1 (en) 2019-03-20
AU2017261847B2 (en) 2023-03-30
AU2017261847A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
SG11201809976PA (en) Protection of plant extracts and compounds from degradation
SG11201906795SA (en) Novel plant cells, plants, and seeds
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201408054RA (en) Pegylated oxm variants
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810192TA (en) Antibacterial compositions
SG11201900545TA (en) Pharmaceutical compounds
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900665VA (en) Cannabis composition
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201908652QA (en) Pharmaceutical compositions
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201811579VA (en) Chemiluminescent substrates
SG11201805423TA (en) Indolinones compounds and their use in the treatment of fibrotic diseases
SG11201903427UA (en) Deodorizing agent comprising zinc neodecanoate
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201807404XA (en) Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease